Randal W. Scott sold $671k of BBIO
director at BridgeBio Pharma, Inc.. 10,000 shares at an average of $67.15, traded May 15, 2026, filed May 19, 2026.
Score components
- +15RoleDirector
- +20Trade size$671k at market
- +10Share of holdings soldSold 46% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-26-000470, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 15, 2026 | MOption exercise Common Stock10b5-1 | +10,000 | $16.75 | $168k | 21,589 | May 19, 2026 |
| May 15, 2026 | SOpen-market sale Common Stock10b5-1 | -6,200 | $66.69 | $413k | 15,389 | May 19, 2026 |
| May 15, 2026 | SOpen-market sale Common Stock10b5-1 | -2,088 | $67.53 | $141k | 13,301 | May 19, 2026 |
| May 15, 2026 | SOpen-market sale Common Stock10b5-1 | -1,512 | $68.23 | $103k | 11,789 | May 19, 2026 |
| May 15, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $69.12 | $14k | 11,589 | May 19, 2026 |
| May 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 21,501 | May 19, 2026 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 13Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $342k 5,004 shares | -35% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $2.8M 39,363 shares | -372% | |
| 40Moderate | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $6.0M 90,240 shares | -93% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -14% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.8M 26,103 shares | -10% | |
| 40Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $888k 13,651 shares | -4% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -13% | |
| 14Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $143k 2,000 shares | -1% | |
| 35Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $6.0M 80,000 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.